Preventive effect of hydrazinocurcumin on carcinogenesis of diethylnitrosamine-induced hepatocarcinoma in male SD rats

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 2115-2121

  Zhao, Ji An ^a   Peng, Li ^a   Geng, Cui Zhi ^a   Liu, Yue Ping ^a   Wang, Xu ^a   Yang, Hui Chai ^a   Wang, Shi Jie ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Diethylnitrosamine; Hepatocarcinoma; Hydrazinocurcumin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CURCUMIN; DIETHYLNITROSAMINE; GAMMA GLUTAMYLTRANSFERASE; HYDRAZINE DERIVATIVE; HYDRAZINOCURCUMIN;

ANALOGS AND DERIVATIVES; ANIMAL; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER; LIVER FUNCTION TEST; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; METABOLISM; PROCEDURES; RAT; SPRAGUE DAWLEY RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CURCUMIN; DIETHYLNITROSAMINE; GAMMA-GLUTAMYLTRANSFERASE; HYDRAZINES; LIVER; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84899094647     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.2115     Document Type: Article

References (40)

1. Yildirim Y, Ozyilkan O, Bilezikci B, et al (2008).Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival. Asian Pac J Cancer Prev, 9, 295-8.
2. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, et al (2009). Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitine-depleted rats. World J Gastroenterol, 15, 1373-80.
3. Anand P, Kunnumakkara AB, Newman RA, et al (2007). Bioavailability of curcumin: problems and promises. Mol Pharm, 4, 807-18.
4. Appiah-Opong R, de Esch I, Commandeur JN, et al (2008). Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem, 43, 1621-31.
5. Bulle F, Mavier P, Zafrani ES, et al (1990). Mechanism of gamma-glutamyl transpeptidase release in serum during intrahepatic and extrahepatic cholestasis in the rat: a histochemical, biochemical and molecular approach. Hepatology, 11, 545-50.
6. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.
7. Devasena T, Rajasekaran KN, Menon VP (2002). Bis-1, 7- (2-hydroxyphenyl)-hepta-1, 6-diene-3, 5-dione (a curcumin analog) ameliorates DMH-induced hepatic oxidative stress during colon carcinogenesis. Pharmacol Res, 46, 39-45.
8. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
9. Gayathri R, Priya DK, Gunassekaran GR, et al (2009). Ursolic acid attenuates oxidative stress-mediated hepatocellular carcinoma induction by diethylnitrosamine in male Wistar rats. Asian Pac J Cancer Prev, 10, 933-8.
10. Greaves P, Irisarri E, Monro AM (1986). Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility. J Natl Cancer Inst, 76, 475-84.
11. Hasegawa R, Takahashi S, Imaida K, et al (1991). Agedependent induction of preneoplastic liver cell foci by 2-acetylaminofluorene, Phenobarbital andacetaminophen in F344 rats initially treated with diethylnitrosamine. Jpn J Cancer Res, 82, 293-97.
12. Huang TS, Lee SC, Lin JK (1991). Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA, 88, 5292-96.
13. Ishida J, Ohtsu H, Tachibana Y, et al (2002). Antitumor agents. Part 214: synthesis and evaluation of curcumin analogues as cytotoxic agents. Bioorg Med Chem, 10, 3481-87.
14. Kang JS (2012). Increased expression of epithelial cell adhesion molecule (EpCAM) in rat hepatic tumors induced by diethylnitrosamine. Asian Pac J Cancer Prev, 13, 3627-30.
15. Kelloff GJ, Lieberman R, Steele VE, et al (1999). Chemoprevention of prostate cancer: concepts and strategies. Eur Urol, 35, 342-50.
16. Kern MA, Sch neweiss MM, Sahi D, et al (2004). Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 25, 1193-99.
17. Kumada T, Nakano S, Takeda I, et al (1997). Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology, 25, 87-92.
18. Lee YK, Park SY, Kim YM (2009). Regulatory effect of the AMPK-COX-2 signaling pathway in curcumin-induced apoptosis in HT-29 colon cancer cells. Ann N Y Acad Sci, 1171, 489-94.
19. Llorente Izquierdo C, Mayoral R, Flores JM, et al (2011). Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme tochemical hepatocarcinogenesis. Am J Pathol, 178, 1361-73.
20. Marx JJM (1996). Toxicology of the blood: Pathophysiology, toxicological pathology and mechanistic aspects, In: Toxicology Principles and Applicants. Edited by Niesink JM, Vries J, Hollinger MA, pp.817-837.
21. Mehta K, Pantazis P, McQueen T, et al (1997). Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs, 8, 470-81.
22. Müller-Decker K (2011). Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev, 30, 343-61.
23. Nagano H (2010). Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology, 78, 142-47.
24. Nair KG, Deepadevi KV, Arun P, et al (1998). Toxic effect of systemic administration of low doses of the plasticizer di- (2-ethyl hexyl) phthalate [DEHP] in rats. Indian J Exp Biol, 36, 264-72.
25. Okuda H (2007). Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol, 21, 161-73.
26. Park TJ, Kim HS, Byun KH, et al (2001). Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16 (INK4A) exon 1 in hepatocellular carcinoma. Mol Carcinog, 30, 138-50.
27. Plummer SM, Holloway KA, Manson MM, et al (1999). Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involvesinhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 18, 6013-20.
28. Rathore R, Jain JP, Srivastava A, et al (2008). Simultaneous determination of hydrazinocurcumin and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal, 46, 374-80.
29. Selvam C, Jachak SM, Thilagavathi R, et al (2005). Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett, 15, 1793-7.
30. Shim JS, Kim DH, Jung HJ, et al (2002). Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem, 10, 2987-92.
31. Singh BN, Singh BR, Sarma BK, et al (2009). Potential chemoprevention of N-nitrosodiethylamine-induced hepatocarcinogenesis by polyphenolics from Acacia nilotica bark. Chem Biol Interact, 181, 20-8.
32. Sivaramakrishnan V, Shilpa PN, Praveen Kumar VR, et al (2008). Attenuation of N-nitrosodiethylamine-induced hepatocellular carcinogenesis by a novel flavonol-Morin. Chem Biol Interact, 171, 79-8.
33. Sreepriya M, Bali G (2005). Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbitalinduced hepatocarcinogenesis in Wistar rats. Fitoterapia, 76, 549-55.
34. Taras D, Blanc JF, Rullier A, et al (2007). Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol, 46, 69-6.
35. Tessitore L, Costelli P, Bonetti G, et al (1993). Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys, 306, 52-8.
36. Theise ND, Curado MP, Franceschi S (2010). Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumors of the Digestive System. Lyon, France: IARC Press: 205-16.
37. Verburg KM, Maziasz TJ, Weiner E, et al (2001). Cox-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther, 8, 49-4.
38. Wang X, Zhang Y, Zhang X, et al (2012). The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition. Int J Oncol, 40, 1189-95.
39. Wang YX, Gao JX, Wang XY, et al (2012). Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biol, 33, 957-66.
40. Yao DF, Dong ZZ, Yao DB, et al (2004). Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration forcarcinogenesis of hepatocytes. Hepatobiliary Pancreat Dis Int, 3, 564-70.